Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form
about
Critical evaluation of paliperidone in the treatment of schizophrenia in Chinese patients: a systematic literature reviewChemistry with spatial control using particles and streams().Profile of paliperidone extended release: review of efficacy and safety data.Paliperidone ER and oral risperidone in patients with schizophrenia: a comparative database analysisPaliperidone ER: a review of the clinical trial data.Treatment satisfaction with paliperidone extended-release tablets: open-label study in schizophrenia patients dissatisfied with previous antipsychotic medicationChronic, constant-rate, gastric drug infusion in nontethered rhesus macaques (Macaca mulatta).Curse of the ghost pills: the role of oral controlled-release formulations in the passage of empty intact shells in faeces. Two case reports and a literature review relevant to psychiatry.Effects of paliperidone extended release on the symptoms and functioning of schizophreniaPaliperidone: the evidence of its therapeutic value in schizophrenia.Paliperidone extended-release: does it have a place in antipsychotic therapy?Japan useful medication program for schizophrenia (JUMPs)-long-term study on discontinuation rate, resolution and remission, and improvement in social functioning rate associated with atypical antipsychotic medications in patients with schizophreniaPaliperidone ER in the Treatment of Borderline Personality Disorder: A Pilot Study of Efficacy and Tolerability.Clinical pharmacology of atypical antipsychotics: an update.Paliperidone extended-release tablets in Chinese patients with schizophrenia: meta-analysis of randomized controlled trials.Treatment response, safety, and tolerability of paliperidone extended release treatment in patients recently diagnosed with schizophreniaA Flexible-Dose Study of Paliperidone ER in Patients With Nonacute Schizophrenia Previously Treated Unsuccessfully With Oral OlanzapineSafety and efficacy of paliperidone extended-release in acute and maintenance treatment of schizophrenia.Costs and effects of paliperidone extended release compared with alternative oral antipsychotic agents in patients with schizophrenia in Greece: a cost effectiveness study.Paliperidone: a new extended-release oral atypical antipsychotic.The pharmacology and safety of paliperidone extended-release in the treatment of schizophrenia.A review of the gastrointestinal therapeutic system (GITS) formulation and its effectiveness in the delivery of antihypertensive drug treatment (focus on nifedipine GITS).Efficacy and Tolerability of Paliperidone Extended-release in the Treatment of First-episode Psychosis: An Eight-week, Open-label, Multicenter Trial.Diagnostic and treatment challenges of chronic fatigue syndrome: role of immediate-release methylphenidate.Expected clinical benefits of paliperidone extended-release formulation when compared with risperidone immediate-release.The pharmacokinetics of a long-acting OROS hydromorphone formulation.Dosing and switching of paliperidone ER in patients with schizophrenia: recommendations for clinical practice.Paliperidone extended-release: a review of efficacy and tolerability in schizophrenia, schizoaffective disorder and bipolar mania.Oral paliperidone: a review of its use in the management of schizoaffective disorder.Oral paliperidone extended-release: chemistry, pharmacodynamics, pharmacokinetics and metabolism, clinical efficacy, safety and tolerability.Pharmacological and clinical profile of recently approved second-generation antipsychotics: implications for treatment of schizophrenia in older patients.Paliperidone extended release: in adolescents with schizophrenia.The pharmacology and formulation of paliperidone extended release.Pharmacokinetic drug evaluation of paliperidone in the treatment of schizoaffective disorder.Paliperidone for the treatment of schizophrenia and schizoaffective disorders - a drug safety evaluation.A prospective, open-label, multicenter study of the clinical efficacy of extended-release hydromorphone in treating cancer pain inadequately controlled by other analgesics.Synchronized and controlled release of metformin hydrochloride/glipizide from elementary osmotic delivery.Predicting pharmacokinetic stability by multiple oral administration of atypical antipsychotics.Initial design and physical characterization of a polymeric device for osmosis-driven delayed burst delivery of vaccines.Feasibility of optimizing trimetazidine dihydrochloride release from controlled porosity osmotic pump tablets of directly compressed cores.
P2860
Q26774421-232FC970-7D6D-4CFE-A44C-E3420EE5C14AQ30528061-E3876710-E4F4-40F4-83A9-8C5FBFA00DC8Q30730686-779B528B-6B40-4281-9663-88B09B457E02Q30998569-5ED8EB0D-4CEA-444C-AE03-CFFE98BD5C5EQ33419885-A1966029-96B9-49E2-8F8B-1A9456962D92Q33595935-99BDC9D9-CB49-45F4-9432-33D5CB9F6F7FQ33755177-FB65C26E-E1DE-4D86-A593-F62B5CA6C6A6Q33949355-0ACD73BB-9B40-41FC-95CD-A0C462BF375EQ34120856-3CED8AA2-0A0D-4968-8F0F-56D0D07BF8B7Q34449894-0B80896B-62FB-4F54-ADA6-F42D41954BCAQ34712339-8AC4ACED-28DD-47F3-AE52-3C1EBCC0A7D6Q35007214-7DB1CAF7-67AC-4D92-9C25-F3A4A01327B9Q35151598-D45FA0AC-A8CC-44D7-A6AB-7ECF71960436Q35728228-E1F30941-4FAC-404F-9049-F978D5B1C57CQ35729122-30086FB0-947E-4308-B24D-3F3CA84DE0B3Q35948848-68F42DE1-7B92-404B-8EA0-3ECA2B49D771Q36628058-273C7E15-855C-4CFC-A26C-ABA386D35297Q36873906-3FFE8A73-197B-4E0F-AAD9-152709DF685FQ36908237-653905C4-45EB-4873-B67B-1960492207AEQ36967269-80BCFA19-87B0-450C-95A8-D43303E35D5FQ36984231-A1230791-535C-4438-B3B2-785210C71624Q37047293-7C44610D-19D5-48C1-8BCC-69BACCD23C4DQ37160642-B3DAB8AD-1C27-44B1-99B0-ED0189926DC2Q37174049-22573F72-A887-4149-A1EA-0F6D289C8392Q37422493-497CBB2B-4638-40B2-AFCD-4C895780AB7AQ37644498-09B67E96-F7B2-4949-9074-EDCD74E23467Q37714573-F631AFBF-6828-4F87-9CC2-FB3278D785BEQ37790388-2891327A-15BB-489A-BB22-ABCA6385E327Q37885980-D8B27937-889A-44E9-A8DB-4D0F19348EB4Q38013250-95CF75BE-A37C-41A7-87FF-8392E40C371DQ38047222-90F03CF3-57F3-4300-97A5-565334D31BF8Q38050832-E642429F-5CAD-44F8-A085-47B337EBD098Q38067139-19D4CD2A-9597-44A9-9D18-247752A13312Q38694725-586CFC20-5FE3-4005-B95A-F03E2D2BFC22Q38989642-051E6C1C-808E-4C77-84E8-B591DF254FDDQ39217581-5E61AB30-3129-4784-B0B9-FFF311B3150BQ39699017-65CFD5A2-63C6-4CA8-90E2-F4FFA9E9507DQ40200910-38550867-4F72-47D0-B45A-78A060CD19B4Q41196877-A5BEB80A-9DC0-408A-BBBD-5935520E3EF6Q41430120-F921DC89-D5A9-464A-A542-EBCE6B9F5CED
P2860
Clinical spectrum of the osmotic-controlled release oral delivery system (OROS), an advanced oral delivery form
description
2006 nî lūn-bûn
@nan
2006 թուականի Հոկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հոտեմբերին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Clinical spectrum of the osmot ...... an advanced oral delivery form
@ast
Clinical spectrum of the osmot ...... an advanced oral delivery form
@en
Clinical spectrum of the osmot ...... an advanced oral delivery form
@nl
type
label
Clinical spectrum of the osmot ...... an advanced oral delivery form
@ast
Clinical spectrum of the osmot ...... an advanced oral delivery form
@en
Clinical spectrum of the osmot ...... an advanced oral delivery form
@nl
prefLabel
Clinical spectrum of the osmot ...... an advanced oral delivery form
@ast
Clinical spectrum of the osmot ...... an advanced oral delivery form
@en
Clinical spectrum of the osmot ...... an advanced oral delivery form
@nl
P2093
P3181
P356
P1476
Clinical spectrum of the osmot ...... an advanced oral delivery form
@en
P2093
Gayatri Sathyan
Robert Conley
Suneel K Gupta
P304
P3181
P356
10.1185/030079906X132613
P407
P577
2006-10-01T00:00:00Z